Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized immune-modulating autologous immunoglobulin therapy for recalcitrant atopic dermatitis
KCT0001597Phase 3Completed
- Sponsor
- National Research Foundation
- Start
- Apr 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Autologous immunoglobulin with Placebo (2 arms). Started Apr 2015; status: completed.
02
Drugs
autologous immunoglobulin
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on KCT0001597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001597.